LivaNova PLC (LIVN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 934 | 1,035 | 1,022 | 1,154 | 1,253 | 1,388 | 1,472 | 1,524 |
| Operating profit | $m | 199 | 198 | ||||||
| Net profit | $m | -349 | -136 | -86 | 18 | 63 | -242 | 189 | 238 |
| EPS reported | $ | -4.45 | 3.39 | ||||||
| Operating cashflow per share | $ | 4.67 | 4.53 | ||||||
| Capex per share | $ | 1.49 | 1.83 | ||||||
| FCF per share | $ | 3.18 | 2.70 | ||||||
| Free cash flow | $m | 173 | 148 | ||||||
| Net debt | $m | -211 | -504 | ||||||
| Book value equity | $m | 1,200 | 1,325 | ||||||
| Book value per share | $ | 22.02 | 23.54 | ||||||
| Number of shares | m | 54.5 | 56.3 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 22.60 | ||||||
| P/B LTM | x | 2.79 | 2.53 | ||||||
| P/S LTM | x | 2.42 | 2.28 | ||||||
| P/FCF LTM | x | 19.36 | 22.61 | ||||||
| EV/EBITDA LTM | x | -24.64 | 17.66 | ||||||
| EV/Sales LTM | x | 2.30 | 2.96 | ||||||
| Earnings Yield LTM | % | -7.23% | +4.42% | ||||||
| FCF Yield | % | +5.16% | +4.42% | ||||||
| Quality | |||||||||
| ROE | % | -20.21% | +15.41% | ||||||
| ROIC | % | +10.90% | +10.19% | ||||||
| Operating margin | % | +14.36% | +13.48% | ||||||
| Gross margin | % | +67.71% | +68.18% | ||||||
| FCF/Sales | % | +12.48% | +10.08% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +192.24% | ||||||
| Sales Growth YoY | % | +10.74% | +17.40% | ||||||
| Net Income Growth YoY | % | - | +198.22% | ||||||
| FCF Growth | % | +27.42% | +9.13% | ||||||
| Operating Profit Growth | % | +54.51% | +53.66% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.37 | 0.42 | ||||||
| Net Debt/EBITDA | x | 1.25 | -0.91 | ||||||
| EBIT/Net interest | x | 4.05 | 4.30 | ||||||
| Net debt/market cap | % | +12.67% | +6.50% | ||||||
| Net debt/Equity | x | -0.18 | -0.38 | ||||||
| Gross debt/equity | x | 0.39 | 0.27 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free